Products
Hexoprenaline is commercially available as a solution for injection (Gynipral). It has been approved in many countries since 1984. Approval for the tablets was revoked on Dec. 31, 2013. This due to the potential cardiovascular side effects that may occur in the mother and child.
Structure and properties
Hexoprenaline (C22H32N2O6, Mr = 420.5 g/mol) is present in drugs as hexoprenaline sulfate.
Effects
Hexoprenaline (ATC R03CC05, ATC G02CA) has selective β2-sympathomimetic properties. It causes uterine muscle relaxation and a decrease or suppression of uterine contractions.
Indications
Hexoprenaline is used to inhibit labor.
Dosage
According to the SmPC. The drug is administered as an intravenous infusion.
Contraindications
For complete precautions, see the drug label.
Adverse effects
The most common possible adverse effects include tremor and tachycardia. Other common side effects:
- Hypokalemia
- Headache
- Palpitations, hypotension, flushing, sweating.
- Nausea
